Umifenovir

Summary

Umifenovir (CHEMBL1214598) is a phase-3 clinical-stage small molecule (ATC J05AX13); indicated across 2 conditions including viral infectious disease and influenza.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J05AX13
• Indications: 2 conditions
• Clinical trials: 8
• Chemistry: 477.4 Da · C22H25BrN2O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1214598
Name	Umifenovir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	131411
ATC	J05AX13
Molecular formula	C22H25BrN2O3S
Molecular weight	477.4
InChIKey	KCFYEAOKVJSACF-UHFFFAOYSA-N

SMILES: CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3

IUPAC name: ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate

Also known as: Arbidol, Umifenovir, SID26662180, arbidol, UMIFENOVIR, ARBIDOL (HYDROCHLORIDE), Arbidol (hydrochloride), ARBIDOL, Arbidol; Umifenovir, umifenovir

Parent form; salt/anhydrous children: CHEMBL5179853

Patent coverage: 587 distinct patent families (1,334 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Hemagglutinin, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Motilin receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Sodium-dependent serotonin transporter.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 25 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	6.27	IC50	540	nM	CHEMBL_ACT_29264654
KCNH2	6.27	IC50	540	nM	CHEMBL_ACT_29264816
KCNH2	6.21	AC50	610	nM	CHEMBL_ACT_25117427
NR1I2	6.04	AC50	920	nM	CHEMBL_ACT_25187973
NR1I2	5.75	AC50	1770	nM	CHEMBL_ACT_25224194
HTR2C	5.58	AC50	2600	nM	CHEMBL_ACT_25131519
MLNR	5.43	AC50	3700	nM	CHEMBL_ACT_25188903
P0DTC2	5.39	IC50	4110	nM	CHEMBL_ACT_24992616
PTGS2	5.26	AC50	5500	nM	CHEMBL_ACT_25165906
PDE4D	5.25	AC50	5600	nM	CHEMBL_ACT_25185027
DRD3	5.17	AC50	6800	nM	CHEMBL_ACT_25193237
HTR2A	5.17	AC50	6700	nM	CHEMBL_ACT_25224903
GAA	5.05	Potency	8912	nM	CHEMBL_ACT_4933978
SLC6A3	5.04	AC50	9100	nM	CHEMBL_ACT_25123658

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	3	MONDO:0005108	EFO:0000763
influenza	3	MONDO:0005812	EFO:0007328

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	5
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01651663	PHASE4	UNKNOWN	A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold
NCT03851991	PHASE4	COMPLETED	The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.
NCT04252885	PHASE4	COMPLETED	The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection
NCT04260594	PHASE4	COMPLETED	Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
NCT04350684	PHASE4	UNKNOWN	Umifenovir in Hospitalized COVID-19 Patients
NCT03787459	PHASE3	COMPLETED	Severe Influenza Trial of ARbidol
NCT06462417	Not specified	RECRUITING	Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis
NCT04273763	Not specified	UNKNOWN	Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).